Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

被引：26

作者：

Westin, Jason R. ^{[1
]}

Tam, Constantine S. ^{[2
,3
]}

Borchmann, Peter ^{[4
]}

Jaeger, Ulrich ^{[5
]}

McGuirk, Joseph P. ^{[6
]}

Holte, Harald ^{[7
]}

Waller, Edmund K. ^{[8
]}

Jaglowski, Samantha ^{[9
]}

Bishop, Michael R. ^{[10
]}

Andreadis, Charalambos ^{[11
]}

Foley, Stephen Ronan ^{[12
]}

Fleury, Isabelle ^{[13
]}

Ho, P. Joy ^{[14
]}

Mielke, Stephan ^{[15
]}

Teshima, Takanori ^{[16
]}

Schuster, Stephen J. ^{[17
]}

Bachanova, Veronika ^{[18
]}

Maziarz, Richard T. ^{[19
]}

Van Besien, Koen ^{[20
]}

Izutsu, Koji ^{[21
]}

Kersten, Marie Jose ^{[22
]}

Magenau, John M. ^{[23
]}

Wagner-Johnston, Nina D. ^{[24
,25
]}

Kato, Koji ^{[26
]}

Corradini, Paolo ^{[27
]}

Han, Xia ^{[28
]}

Tiwari, Ranjan ^{[29
]}

Agoulnik, Sergei ^{[30
]}

Eldjerou, Lamis K. ^{[28
]}

Pacaud, Lida Bubuteishvili ^{[28
]}

Salles, Gilles A. ^{[31
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[2] St Vincents Hosp, Melbourne, Vic, Australia

[3] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[5] Med Univ Vienna, Dept Med 1, Clin Div Hematol & Hemostaseol, Vienna Gen Hosp, Vienna, Austria

[6] Univ Kansas Hlth Syst, Dept Internal Med, Kansas City, KS USA

[7] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[8] Emory Clin, Div Hematol Oncol, Atlanta, GA 30322 USA

[9] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA

[10] Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA

[11] Univ Calif San Francisco, Dept Med, Helen Diller Family Comp, San Francisco, CA 94143 USA

[12] McMaster Univ, Hamilton, ON, Canada

[13] Univ Paris Diderot, Montreal, PQ, Canada

[14] Royal Prince Alfred Hosp, Inst Haematol, Dept Haematol, Camperdown, NSW, Australia

[15] Univ Hosp Wurzburg, Wurzburg, Germany

[16] Hokkaido Univ Hosp, Dept Hematol, Sapporo, Hokkaido, Japan

[17] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA

[18] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

[19] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[20] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA

[21] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[22] Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands

[23] Univ Michigan, Ann Arbor, MI 48109 USA

[24] Johns Hopkins Sch Med, Baltimore, MD USA

[25] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[26] Kyushu Univ Hosp, Dept Med & Biosyst Sci, Fukuoka, Japan

[27] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[28] Novartis Pharmaceut, E Hanover, NJ USA

[29] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India

[30] Novartis Inst Biomed Res, Cambridge, MA USA

[31] Lyon Sud Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-129107

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4103

引用

页数：6

共 50 条

[21] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Friedberg, Jonathan W.
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
[22] Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study
Schuster, Stephen J.
Bishop, Michael R.
Tam, Constantine S.
Borchmann, Peter
Jaeger, Ulrich
Waller, Edmund K.
Holte, Harald
McGuirk, Joseph
Jaglowski, Samantha
Tobinai, Kensei
Andreadis, Charalambos
Fleury, Isabelle
Mielke, Stephan
Teshima, Takanori
Westin, Jason R.
Bachanova, Veronika
Foley, Stephen Ronan
Ho, Joy
Magenau, John M.
Wagner-Johnston, Nina
Kato, Koji
Kersten, Marie Jose
van Besien, Koen
Chu, Jufen
Jary, Aline
Anak, Oezlem
Salles, Gilles A.
Maziarz, Richard T.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[23] Efficacy of Salvage Radiotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Wang, S.
Chen, J. Y.
Cao, W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E471 - E472
[24] Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
Wang, Shu-Bei
Chen, Jia-Yi
Zhao, Wei-Li
Kirova, Youlia M.
Cao, Wei-Guo
TRANSLATIONAL CANCER RESEARCH, 2019, 8 (04) : 1019 - 1026
[25] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Maria Jose
Schuster, Stephen J.
Salles, Gilles
Maziarz, Richard T.
Anak, Ozlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
CANCER RESEARCH, 2018, 78 (13)
[26] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
Habermann, T.
Lossos, I.
Justice, G.
Tuscano, J.
Cole, C.
Vose, J.
Pietronigro, D.
Takeshita, K.
Ervin-Haynes, A.
Zeldis, J.
Wiernik, P.
ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
[27] BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND
Hollmann, S.
Painter, C.
Hogan, A.
Morten, P.
Goyert, N.
Vieira, J.
Slowley, A.
Jousseaume, E.
El Ouagari, K.
Zhang, J.
Jewitt, K.
Ma, Q.
VALUE IN HEALTH, 2018, 21 : S26 - S26
[28] Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Batlevi, Connie Lee
Nos, Grigorii
Kotlov, Nikita
Sorokina, Maria
Okwali, Michelle
Bagaev, Alexander
Michaud, Laure
Shah, Gunjan L.
Shouval, Roni
Tomas, Ana Alarcon
Ewalt, Mark D.
Belova, Ekaterina
Degryse, Sandrine
Tazearslan, Cagdas
Podsvirova, Svetlana
Love, Anna Mooney
Postovalova, Ekaterina
Fowler, Nathan H.
Perales, Miguel-Angel
Schoder, Heiko
Dogan, Ahmet
Arcila, Maria E.
Salles, Gilles
Sauter, Craig S.
BLOOD, 2022, 140 : 9228 - 9229
[29] A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Flinn, Ian W.
Bartlett, Nancy L.
Blum, Kristie A.
Ardeshna, Kirit M.
LaCasce, Ann S.
Flowers, Christopher R.
Shustov, Andrei R.
Thress, Kenneth S.
Mitchell, Patrick
Zheng, Fred
Skolnik, Jeffrey M.
Friedberg, Jonathan W.
EUROPEAN JOURNAL OF CANCER, 2016, 54 : 11 - 17
[30] A Phase ll Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Flinn, Ian
Bartlett, Nancy L.
Blum, Kristie A.
Ardeshna, Kirit M.
LaCasce, Ann
Flowers, Christopher R.
Shustov, Andrei R.
Thress, Kenneth
Zheng, Fred
Skolnik, Jeffery
Friedberg, Jonathan W.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →